| Literature DB >> 25561988 |
Feng Gao1, Qicai Liu2, Zhi-Bo Zhang3, Guozhong Liu3, Ruiqing Chen4, Jing Chen2, Sheng Zhang1.
Abstract
INTRODUCTION: Type 1 autoimmune pancreatitis (AIP) is the pancreatic manifestation of a systemic fibroinflammatory IgG4-related disease. Accurate diagnosis of AIP can avoid major hepatobiliary and pancreatic surgery as it respond dramatically to corticosteroid therapy. AIM: This research investigated the feasibility of using peripheral blood cell immunohistochemistry, serum IgG4, T-cell receptor (TCR) and serum isoelectric focusing electrophoresis in the screening of type 1 autoimmune pancreatitis (AIP).Entities:
Keywords: TCR; peripheral blood cell immunohistochemistry; serum IgG4; serum isoelectric focusing electrophoresis; type 1 autoimmune pancreatitis
Year: 2014 PMID: 25561988 PMCID: PMC4280412 DOI: 10.5114/wiitm.2014.44290
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Imaging features and specificity pathology of patients
| Case | Gender | Age | Organ involvement and performance | Imaging features | Specificity pathology | Dispose | Lapse |
|---|---|---|---|---|---|---|---|
| 1 | Male | 54 | Chronic pancreatitis, chronic cholecystitis, jaundice | Atrophy of pancreas, pancreatic uncinate multiple calcification, dilated pancreatic duct | (Pancreatic tissue) chronic pancreatitis, lymph, infiltration of plasma cells 45% | Operation, postoperative prednisolone 35 mg/day | Improvement |
| 2 | Male | 43 | Autoimmune pancreatitis, jaundice | Pancreatic duct beaded enlargement | (Pancreatic puncture) lymph, infiltration of plasma cells, IgG4 positive cells 45% | Prednisolone 40 mg/day | Improvement |
| 3 | Female | 38 | Interstitial pneumonia, chronic pancreatitis, cholangitis, jaundice | Diffuse enlargement of the pancreas, nodular cirrhosis, cholecystitis | (Pancreatic puncture) infiltration of plasma cells, IgG4 positive cells 52% | Prednisolone 45 mg/day | Relieve |
Laboratory examination results of patients
| Case | Weight loss (kg/12 months) | ANA (< 1.0) | IgG (0–16) | IgG4 (0.08–1.4 g/l) | IgE (0–100 IU/ml) | CRP (0–8 mg/l) | Ca125 (0–35 U/ml) | Ca199 (0–34 U/ml) |
|---|---|---|---|---|---|---|---|---|
| 1 | 6 | 0.25 | 28.63 | 12.335 | 985 | 10.5 | 22.45 | 22.15 |
| 2 | 5 | 0.13 | 52.36 | 34.400 | 1250 | 5.6 | 15.11 | 10.25 |
| 3 | 8 | 0.96 | 21.40 | 16.852 | 377 | 15.6 | 38.85 | 12.36 |
Photo 1Serum isoelectric focusing electrophoresis of AIP and pancreatic cancer. A – IgG4 and IgG staining of no. 1 patients with AIP (left: IgG4, right IgG staining), a mirror image of distribution. B – IgG4 and IgG staining of no. 2 patients with AIP (left: IgG4, right IgG staining), roughly mirroring distribution. C – IgG4 staining of patients with pancreatic cancer (left) and no. 3 patient with type 1 AIP (right)
Photo 2IgG and IgG4 stain of peripheral blood cell. A – IgG4 stain of blood cell with direct application of EDTA anticoagulation. B – IgG stain of blood cell with direct application of EDTA anticoagulation. C – IgG4 stain of blood cell after treatment with 20% glacial acetic acid. D – IgG stain of blood cell after treatment with 20% glacial acetic acid
Figure 1Serum TCR in AIP, pancreatic cancer, and normal controls. A – Relationship between serum IgG4 and treatment in AIP. B – Relationship between the percentage of IgG4/IgG positive cells in peripheral blood cells and treatment in AIP. C – Pancreatic cancer, the difference in serum TCR between AIP, pancreatic cancer and normal control group